Get the Stockscreener App
2.75
0.00%
0.00
After Hours:
2.75
Aprea Therapeutics Inc stock is traded at $2.75, with a volume of 15,783.
It is up +0.00% in the last 24 hours and down -19.80% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$2.75
Open:
$2.81
24h Volume:
15,783
Relative Volume:
1.82
Market Cap:
$14.83M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.4973
EPS:
-5.53
Net Cash Flow:
$-12.27M
1W Performance:
-10.13%
1M Performance:
-19.80%
6M Performance:
-58.89%
1Y Performance:
-34.00%
1-Day Range:
$2.5999
$2.85
1-Week Range:
$2.25
$3.15
52-Week Range:
$2.25
$8.8465
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
617-463-9385
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Aprea Therapeutics to Present at Lytham Partners Fall Investor Conference - MSN
Aprea Therapeutics to Present at Lytham Partners Fall Investor Conference - MyChesCo
Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - EIN News
Aptar's N-Sorb accepted into FDA Emerging Technology Program - Investing.com India
Sagefield Capital LP Purchases New Stake in Patterson-UTI Energy, Inc. (NASDAQ:PTEN) - Defense World
Analysts’ Weekly Ratings Changes for Adicet Bio (ACET) - Defense World
Patterson-UTI Energy Inc [PTEN] is -22.50% lower this YTD. Is it still time to buy? - The DBT News
Market Watch: Applied Dna Sciences Inc (APDN)’s Noteworthy Gain, Closing at 1.25 - The Dwinnex
Unicycive Therapeutics (NASDAQ:UNCY) and Aprea Therapeutics (NASDAQ:APRE) Head to Head Comparison - Defense World
Larimar Therapeutics to Present Groundbreaking Nomlabofusp Studies at ICAR Conference - MyChesCo
Adicet Bio shares hold neutral rating amid positive study data By Investing.com - Investing.com South Africa
Adicet Bio (NASDAQ:ACET) Rating Reiterated by Wedbush - MarketBeat
Adicet Bio (NASDAQ:ACET) Receives Neutral Rating from HC Wainwright - Defense World
Adicet Bio's (ACET) "Neutral" Rating Reiterated at HC Wainwright - MarketBeat
APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com Australia
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com
APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com Canada
APRE stock touches 52-week low at $2.86 amid market challenges - Investing.com UK
Applied Therapeutics: FDA Stance Change For Advisory Panel Bodes Well For Review (APLT) - Seeking Alpha
Applied Therapeutics Stock Soars As FDA Scraps Panel Meeting For Its Inherited Metabolic Disorder Drug - Benzinga
Applied Therapeutics Shares Rise as Drug Continues with Priority Review - MarketWatch
Applied DNA Sciences (NASDAQ:APDN) Upgraded to Sell by StockNews.com - Defense World
Ascendis Pharma price target raised to $289 from $264 at Wells Fargo - TipRanks
Aprea Therapeutics to Present at H.C. Wainwright Investment Conference - MSN
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 - GlobeNewswire
Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 - Yahoo Finance
UPDATE – Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - ForexTV.com
Doylestown Cancer Pharma Moves Closer to Starting Clinical Testing on Its 3rd Experimental Cancer Treatment - BUCKSCO.Today
APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com India
APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com Canada
APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com UK
APRE stock touches 52-week low at $3.17 amid market challenges - Investing.com
Aprea Therapeutics to Present at H.C. Wainwright Investment Conference - MyChesCo
Myelodysplastic Syndrome (MDS) Drugs Market Research Report Explores 2024-2033 | Size, Growth, Demand, Trends - WhaTech
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference - ForexTV.com
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in July - Defense World
Biora Therapeutics, Inc. (NASDAQ:BIOR) Forecasted to Post Q3 2024 Earnings of ($0.42) Per Share - Defense World
Q3 2024 Earnings Estimate for Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Issued By HC Wainwright - Defense World
Q3 2024 EPS Estimates for Astria Therapeutics, Inc. Decreased by HC Wainwright (NASDAQ:ATXS) - Defense World
Wedbush Comments on Aerovate Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:AVTE) - Defense World
Aprea Therapeutics (NASDAQ:APRE) Releases Earnings Results, Beats Estimates By $0.05 EPS - Defense World
Aprea Therapeutics’ (APRE) Outperform Rating Reaffirmed at Wedbush - Defense World
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Progress in Clinical Trials - MyChesCo
Aprea Therapeutics (NASDAQ:APRE) Given “Buy” Rating at HC Wainwright - Defense World
APRE stock touches 52-week low at $3.22 amid market challenges - Investing.com Canada
APRE Stock Earnings: Aprea Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
APRE stock touches 52-week low at $3.22 amid market challenges - Investing.com
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates - MSN
APRE stock touches 52-week low at $3.22 amid market challenges - Investing.com UK
Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):